Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trimebutine - Labopharm

Drug Profile

Trimebutine - Labopharm

Alternative Names: Modulon SR; Trimebutine maleate

Latest Information Update: 10 Oct 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Axcan Pharma; Labopharm
  • Developer Labopharm
  • Class Antispasmodics; Benzoic acids; Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 01 Sep 2004 Discontinued - Phase-I for Irritable bowel syndrome in Canada (PO)
  • 26 Sep 2002 Phase-I clinical trials in Irritable bowel syndrome in Canada (unspecified route)
  • 24 Jul 2002 Labopharm and Axcan have signed a letter of intent on a global licensing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top